Strategic alliances
Strategic alliances rarely fail because the science is weak. They fail because responsibilities are unclear, quality expectations are misaligned, or risks are discovered too late—when timelines and deal structures are already locked. In practice, “quality” in alliances is not a documentation exercise. It is a way to protect regulatory credibility, operational continuity, and value while organisations change shape.
Here we describe how QAlliance can support due diligence (pre‑deal), acquisitions, and partnership/co‑sponsorship support.
When stategic alliances become a quality risk
You need a realistic view of compliance maturity, inspection history, and data credibility—without relying on high‑level assurances.
Acquisition planning and integration
You need to identify critical gaps early and define integration steps across GxP areas so compliance does not become a post‑close surprise.
Partnerships with shared responsibility
You need aligned GxP expectations, workable oversight, and clear quality roles across parties—especially in co‑sponsorship and change of sponsor scenarios.
Vendor‑heavy operating models
Alliances increase dependence on CROs, CDMOs, laboratories, and logistics providers—raising the bar for oversight and quality agreements.
What 'good' looks like in alliance quality work
Clarity on responsibilities and decision rights
Who owns what, who decides what, and how escalation works across organisational boundaries. Partnership models fail when accountability is assumed rather than operationalised.
How QAlliance typically supports
GxP-focused due dilligence (pre-deal)
We support buyers, investors, and partners with structured quality due diligence across:
- clinical development and sponsor oversight
- manufacturing, testing, and supply chains
- laboratories and data integrity
- quality systems, governance, and operations
Our assessments identify:
- actual compliance status
- underlying root causes of gaps
- remediation complexity and cost implications
The outcome is a clear, decision‑relevant quality risk profile, not just a list of findings.
Acquisitions (transition and integration)
During acquisitions, we support:
- identification of critical compliance gaps
- review and alignment of quality agreements
- transition planning for quality systems and responsibilities
Post‑transaction, we assist with:
- quality system harmonisation
- governance and oversight alignment
- risk‑based integration planning
This helps ensure continuity of compliance while avoiding unnecessary disruption.
Partnership and co‑sponsorship
In partnerships, co‑development, and co‑sponsorship models, we support:
- assessment of each party’s quality maturity
- alignment of GxP standards and expectations
- definition of clear accountability and oversight
- preparation and execution of change of sponsorship activities in clinical trials
These activities are critical to ensuring that shared responsibility does not translate into shared risk.
Examples of alliance-related challenges we help resolve
“The QMS looks compliant, but we don’t trust it.”
We assess whether controls are embedded in operations or only documented.
“Findings exist — but we don’t know what they mean commercially.”
We translate compliance gaps into remediation effort, timeline, and risk.
“Integration will stretch both organisations.”
We identify where systems can be aligned pragmatically versus where separation should be maintained.
“Shared responsibility feels unclear.”
We help define and operationalise accountability in partnership and co‑sponsorship models.
What to expect from us
Expect:
- Independent, senior judgement
- Assessments that regulators would recognise as credible
- Quality insights translated into business‑relevant risk
Don’t expect:
- Checklist‑only due diligence
- Reassurance without supporting evidence
- Generic remediation advice detached from operating reality
If you are entering a deal, partnership, or co‑sponsorship, quality risk is rarely a side topic. It is often a value driver—or a value leak. Starting early gives you options: in deal structure, in remediation planning, and in how you protect credibility during transition.
Strategic alliances tend to expose gaps across multiple areas, so this service naturally connects to:
- governance and leadership (decision authority and accountability)
- quality systems (structure and scalability)
- operational quality (execution and control)
- audits and inspections (compliance track record)
- pre‑clinical and clinical quality (data and development credibility)
Transaction‑related quality findings often reflect pre‑existing structural issues, not isolated deficiencies.